Posters/Publications

February 13, 2018 in PUBLICATIONS

Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN (Presented at the Keystone Symposium on Organ Crosstalk in Obesity and NAFLD, Jan. 21-25, 2018 Keystone, CO, Poster #3028)

Read More
October 23, 2017 in PUBLICATIONS

Fatty Acid Synthase Inhibitor TVB-3664 Reverses Multiple Components of Diet Induced Nonalcoholic Steatohepatitis in Mice Treated With or Without Co-Administered Pirfenidone and Reduces Collagen Accumulation in Bleomycin-Induced Murine Skin Fibrosis (Presented at The Liver Meeting 2017®, Washington, DC, Oct 20-24, Presidential Poster of Distinction, Abstract #1994).

Read More
October 23, 2017 in PUBLICATIONS

Pharmacologic Inhibition of FASN Reverses Diet-Induced Steatohepatitis in Mice and Inhibits Lipogenesis in Humans (Presented at The Liver Meeting 2017®, Washington, DC, Oct 20-24, Abstract #1972).

Read More
May 2, 2017 in PUBLICATIONS

Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for NASH treatment (Presented at The International Liver Congress, Amsterdam, NL April 18-23, 2017, Late Breaking Abstract LB427)

Read More
December 12, 2016 in PUBLICATIONS

Heavily Pre-Treated Breast Cancer Patients Show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor TVB-2640 in Combination with Paclitaxel. (Presented at the San Antonio Breast Cancer Symposium on Saturday Dec. 10, 2016, abstract number P6-11-09)

Read More
November 11, 2016 in PUBLICATIONS

Pharmacological inhibition of FASN Prevents High Fat Diet Induced Liver Damage in Mice and Significantly Reduces de novo Lipogenesis in Humans (Presidential Poster of Distinction presented at the AASLD Meeting on Sunday November 13, 2016, Abstract #1547)

Read More
November 8, 2016 in PUBLICATIONS

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase Inhibitor, TVB-2640 (Presented at the NCRI Cancer Conference on Tuesday Nov. 8, 2016)

Read More
June 1, 2016 in PUBLICATIONS

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 (Poster and Poster Discussion Sessions at the ASCO Meeting on Sunday June 5, 2016, Abstract #2512, Board #212)

Read More
April 19, 2016 in PUBLICATIONS

FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS-mutant NSCLC patients in a phase I study (Poster Presentation at AACR Meeting on Monday Apr 18, 2016 1:00 PM, Abstract number LB-214)

Read More
April 19, 2016 in PUBLICATIONS

Preclinical studies characterize tumor type sensitivity to FASN inhibition and the mechanism and efficacy of novel drug combinations with TVB-2640 (Poster Presentation at AACR Meeting on Wednesday, April 20, 2016, Abstract number 4743)

Read More
March 24, 2016 in PUBLICATIONS

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640” presented by Dr. Manish Patel at the Targeted Anticancer Therapies (TAT) Congress on Wednesday March 23, 2016 at 12 noon EDT

Read More
March 2, 2016 in PUBLICATIONS

Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement (Abstract #1022 and Short Presentation at Keystone Symposium, “New Frontiers in Understanding Tumor Metabolism” February 21-25, 2016, Banff, Alberta, Canada)

Read More
November 8, 2015 in PUBLICATIONS

FASN inhibition studies in preclinical tumor models identify biomarkers that align with in vitro and in vivo sensitivity to TVB-2640 (Poster Presentation at AACR-NCI-EORTC meeting on Sunday Nov 8, 2015)

Read More
November 7, 2015 in PUBLICATIONS

Biomarker Analyses from Dose Escalation Phase of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients (Poster presented at AACR-NCI-EORTC Meeting on Saturday, Nov 7, 2015)

Read More
October 27, 2015 in PUBLICATIONS

A First-In-Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor TVB-2640 Results of Dose Escalation in Mono and Combination and Evidence of Preliminary Activity (Poster presentation at AACR-NCI-EORTC Meeting Session A on Friday Nov 6, 2015 12:15 PM – 3:15 PM)

Read More
October 12, 2015 in PUBLICATIONS

ESMO 2015 Oral Presentation: A First-In-Human Study of the First-In- Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640, as Monotherapy or in Combination

Read More
July 17, 2015 in PUBLICATIONS

Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression (Paper, EBioMedicine)

Read More
July 10, 2015 in PUBLICATIONS

Diacylglycerol Metabolism and Signaling Is a Driving Force Underlying FASN Inhibitor Sensitivity in Cancer Cells (Paper, ACS Chemical Biology)

Read More
June 4, 2015 in PUBLICATIONS

Translational Studies of a First-in-class FASN Inhibitor, TVB-2640, Linking Preclinical Studies to Clinical Laboratory Observations in Solid Tumor Patients. (Poster, AACR Special Conference on Metabolism and Cancer 2015)

Read More
June 4, 2015 in PUBLICATIONS

First-in-Human Investigation of the Oral First-in-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640. (Poster, ASCO 2015)

Read More
April 20, 2015 in PUBLICATIONS

Discovery of tumor types highly susceptible to FASN inhibition and biomarker candidates for clinical analysis. (Poster, AACR 2015)

Read More
April 20, 2015 in PUBLICATIONS

Biomarker and PK/PD analyses of first-in-class FASN inhibitor TVB-2640 in a first-in-human phase 1 study in solid tumor patients. (Poster, AACR 2015)

Read More
April 20, 2015 in PUBLICATIONS

Report of a First-In-Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640. (Poster, AACR 2015)

Read More
December 3, 2012 in PUBLICATIONS

3­‐V Biosciences presented two publications at AASLD

3­‐V Biosciences presented two publications at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting®) held November 9‐13 in Boston, Massachusetts. BACKGROUND:…
Read More